MA55280A - Formulation solide de modulateur d'assemblage de capside - Google Patents

Formulation solide de modulateur d'assemblage de capside

Info

Publication number
MA55280A
MA55280A MA055280A MA55280A MA55280A MA 55280 A MA55280 A MA 55280A MA 055280 A MA055280 A MA 055280A MA 55280 A MA55280 A MA 55280A MA 55280 A MA55280 A MA 55280A
Authority
MA
Morocco
Prior art keywords
solid formulation
assembly modulator
capside
capside assembly
modulator
Prior art date
Application number
MA055280A
Other languages
English (en)
Inventor
Michaël Bertil S Anné
Claire Elisabeth Balmain
Maria Jansens
Oliver Lenz
Abhishek Singh
Jan Snoeys
Dycke Frederic Anne R Van
Joris Jozef Vandenbossche
Dominique Josiane W Verstraete
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/000231 external-priority patent/WO2019175657A1/fr
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA55280A publication Critical patent/MA55280A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA055280A 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside MA55280A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP2019056348 2019-03-13
PCT/IB2019/000231 WO2019175657A1 (fr) 2018-03-14 2019-03-13 Schéma posologique de modulateur d'assemblage de capside
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP19197566 2019-09-16

Publications (1)

Publication Number Publication Date
MA55280A true MA55280A (fr) 2022-01-19

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055280A MA55280A (fr) 2019-03-13 2020-03-13 Formulation solide de modulateur d'assemblage de capside

Country Status (16)

Country Link
EP (1) EP3937928A1 (fr)
JP (1) JP2022524819A (fr)
KR (1) KR20210137484A (fr)
CN (1) CN113557016A (fr)
AU (1) AU2020235442A1 (fr)
BR (1) BR112021017525A2 (fr)
CA (1) CA3132095A1 (fr)
CR (1) CR20210481A (fr)
EC (1) ECSP21067052A (fr)
IL (1) IL286209A (fr)
JO (1) JOP20210250A1 (fr)
MA (1) MA55280A (fr)
MX (1) MX2021011030A (fr)
PE (1) PE20212107A1 (fr)
SG (1) SG11202109710QA (fr)
WO (1) WO2020183020A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
MX2020009531A (es) * 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI733288B (zh) 2013-05-17 2021-07-11 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
MX2020009531A (es) * 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.

Also Published As

Publication number Publication date
PE20212107A1 (es) 2021-11-04
BR112021017525A2 (pt) 2021-11-23
MX2021011030A (es) 2021-10-13
CA3132095A1 (fr) 2020-09-17
EP3937928A1 (fr) 2022-01-19
JOP20210250A1 (ar) 2023-01-30
ECSP21067052A (es) 2021-11-18
KR20210137484A (ko) 2021-11-17
CR20210481A (es) 2021-10-25
CN113557016A (zh) 2021-10-26
JP2022524819A (ja) 2022-05-10
WO2020183020A1 (fr) 2020-09-17
IL286209A (en) 2021-10-31
SG11202109710QA (en) 2021-10-28
AU2020235442A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
EP3576737A4 (fr) Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte
EP3877521A4 (fr) Formulations de nanoparticules lipidiques
EP3877522A4 (fr) Formulations de nanoparticules lipidiques
EP3479431A4 (fr) Compositions d'électrolyte solide
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
EP3926701A4 (fr) Panneau d'affichage
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
MA52019A (fr) Schéma posologique de modulateur d'assemblage de capside
MA53924A (fr) Modulateurs de l'expression d'apol1
SI3927315T1 (sl) Okusne formulacije
EP3601569A4 (fr) Modulateurs de l'expression de pcsk9
EP3886820B8 (fr) Formulations de capsules
MA55015A (fr) Formulations pharmaceutiques
EP3682420A4 (fr) Construction d'images de visages d'utilisateurs par assemblage d'images non chevauchantes
EP3986415A4 (fr) Formulations d'ibogaïne
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques
EP3982415A4 (fr) Panneau d'affichage
EP3817750A4 (fr) Compositions d'associations de cannabidiol
EP3914234A4 (fr) Compositions pharmaceutiques
EP4013441A4 (fr) Formulations de larazotide
EP4015001A4 (fr) Composition pharmaceutique orale
EP3911315A4 (fr) Composition de mélatonine micronisée solide
MA55280A (fr) Formulation solide de modulateur d'assemblage de capside
EP3977855A4 (fr) Composition microbicide stable
EP3899996A4 (fr) Compositions d'électrolyte